Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib and cisplatin may make tumor cells more sensitive to radiation therapy. Giving erlotinib together with cisplatin and radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib when given together with cisplatin and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-03
- Completion
- 2008-03
Outcome
Outcome not reported
Stopped (Enrollment): “Withdrawn due to lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 100 mg/m2 | Oral |
| Subject | Erlotinib | Small molecule | 125 mg/m2 | Oral |
| Subject | Erlotinib | Small molecule | 150 mg/m2 | Oral |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |